

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION ISSUANCE OF PERPETUAL BONDS IN THE PRC

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that, China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a non-wholly-owned subsidiary of the Company, has issued perpetual bonds in the PRC (the “**2024 Perpetual Bonds**”) pursuant to the approval from China Securities Regulatory Commission (Zheng Jian Xu Ke [2024] No. 1356) on the public issuance of corporate bonds by CR Pharmaceutical Commercial to qualified investors in the PRC.

The 2024 Perpetual Bonds shall be issued in an aggregate principal amount of not more than RMB3 billion. Two varieties of the 2024 Perpetual Bonds are issued, where the size of variety one is RMB2.5 billion, with an initial term of three years with a coupon rate of 2.15% per annum; and the size of variety two is RMB500 million, with an initial term of five years with a coupon rate of 2.26% per annum. The aforesaid initial term of the two varieties of 2024 Perpetual Bonds may be extended or repaid in full at the end of their respective initial term at the election of CR Pharmaceutical Commercial. Each of CR Pharmaceutical Commercial and the 2024 Perpetual Bonds has received “AAA” rating from an independent credit rating agency, namely China Chengxi International Credit Ratings Co., Ltd. (中誠信國際評級有限責任公司). The net proceeds raised from the issuance of 2024 Perpetual Bonds will be used for the repayment of existing corporate bonds issued by CR Pharmaceutical Commercial.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 11 December 2024

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.